<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The retrospective evaluation of bone marrow biopsies of 569 patients with primary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>--pMDS--revealed 256 <z:hpo ids='HP_0005505'>refractory anemias</z:hpo>--RA--, 52 <z:hpo ids='HP_0004828'>refractory anemias with ringed sideroblasts</z:hpo>--<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>--, 133 <z:hpo ids='HP_0005505'>refractory anemias</z:hpo> with excess of blasts--<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>--, 52 <z:hpo ids='HP_0005505'>refractory anemias</z:hpo> with excess of blasts in transformation--<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t--, and 53 <z:hpo ids='HP_0011010'>chronic</z:hpo> myelo-monocytic <z:hpo ids='HP_0001909'>leukemias</z:hpo>--CMMOL--according to FAB-criteria, 23 patients were not otherwise specified (<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>: not otherwise specified--<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>.NOS--) </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>-patients had the best prognosis (median survival 41.9 months, incidence of <z:hpo ids='HP_0001909'>leukemia</z:hpo> 3.8%), followed by RA-patients (26.5 months, 16.4%), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>.NOS-patients (22.4 months, 21.7%), CMMOL-patients (12.5 months, 49.1%) </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>- and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t-patients had the worst prognosis (median survival time 8.5 and 4.6 months, incidence of <z:hpo ids='HP_0001909'>leukemia</z:hpo> 42.1% and 57.7%, respectively) </plain></SENT>
<SENT sid="3" pm="."><plain>But the survival times showed a considerable range in each FAB-subgroup with 0-154 months in RA or 0-52 months in CMMOL </plain></SENT>
<SENT sid="4" pm="."><plain>To forecast life expectancy more precisely, a scoring system was developed using nine histopathological parameters, among which the three most important ones were determined: quantity of myeloblasts, <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> and ALIP's </plain></SENT>
<SENT sid="5" pm="."><plain>The scoring system allows a determination of three risk groups with significantly different survival times </plain></SENT>
<SENT sid="6" pm="."><plain>It is valid also for patients without increase of myeloblasts (&lt; 5% myeloblasts in the bone marrow) and identifies high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients in this group </plain></SENT>
<SENT sid="7" pm="."><plain>By this proposed scoring system, a prognostic approval in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> can be achieved applying histopathology without regarding further methods herewith presenting a system which could be considered independently from hematologic, cytological or laboratory data </plain></SENT>
</text></document>